Dynavax Technologies Corp. Appoints Ryan Spencer As Interim Chief Financial Officer

Apr 01, 2024•over 1 year ago

Position

Chief Financial Officer

Company

Dynavax Technologies

Ryan Spencer

EmeryvilleBiopharmaBiotechnology

Description

Dynavax Technologies Corporation has appointed Ryan Spencer as the Interim Chief Financial Officer during Kelly MacDonald’s maternity leave, starting April 1, 2024.

Company Information

Company

Dynavax Technologies

Location

Emeryville, California, United States

About

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Ryan hidden

hidden